The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Novo Nordisk markets its semaglutide drugs as Ozempic pre ...

Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...